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compared to negative margin status was found as negative prognostic 
factors on overall survival (p=0.021). On multivariate analysis, none of 
the variables were found as significant. Median progression free 
survival time was 43 (27.4-55) months. On univariate analyisis, 
patients with paranasal sinus tumor was found worse progression free 
survival compared to other site tumors (p=0.027).  
Conclusions: Although survival rates with surgery and radiotherapy 
are relatively high and lymph node metastasis are rare, it is difficult 
to manage the disease because of its propensity for distant 
metastasis. Advanced stage with positive resection margin are 
associated with poor prognosis. 
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Purpose/Objective: SABR is increasingly considered as a standard of 
care in medically inoperable patients with early stage peripheral lung 
tumour(s). Radiation pneumonitis (RP) is more of a clinical concern in 
this population due their background lung disease .Though dosimetric 
lung parameters for conventional radiotherapy are better defined , 
such data in SABR group is limited. We present an update of a 
previous study assessing correlation between clinical toxicity and 
abnormal dosimetric parameters with more patient numbers and 
longer follow up. 
Materials and Methods: 209 patients were treated at St.James’s 
Institute of Oncology, Leeds, UK with three risk adapted SABR 
fractionations 54Gy in 3, 55Gy in 5 and 60Gy in 8 fractions from 
September 2009 to April 2012.UK SABR Consortium dose constraints 
were used for these different fractionation schedules. Various 
dosimetric parameters like R100 (ratio of 100% isodose volume to 
PTV), R50, V20, mean lung dose and D2cm(maximum dose 2cm from 
PTV in any direction) were computed for all the patients and where 
there is deviation from constraints, clinical toxicity was evaluated and 
graded according to Common Toxicity Criteria v.4.0. 
Results: At the time of analysis median follow up for the group was 21 
months (IQR 6-23 months). Mean lung dose in patients with <grade 
2(G2) toxicity was 4.2 Gy and 3.6Gy in patients with ≥G2 lung toxicity. 
50 patients (23%) had ≥ G 2 early lung toxicity (41patients G2, 9 
patients had G3 toxicity). Only 2 out of 23 patients(pts) with abnormal 
V20 developed G2 pneumonitis which resolved with steroids. 7 patients 
with high R100 (33%) developed G1to G3 early lung toxicity (2 pts G2, 
1pt-G3).The one patient with grade 3 toxicity improved with steroids. 
None of the 5 patients with high R50 had RP. Out of 30 patients with 
high D2cm (surrogate for rib dose), only 3 patients developed rib 
fractures. Mean FEV1 for patients with <G2 lung toxicity was 
1.3litres/min (0.5-3.9) and 1.2 litres/min (0.59-2.2) for patients with 
≥G2 toxicity. Median Medical Research Council (MRC) breathlessness 
score was 3.75 for patients with ≥ G2 toxicity and 3.5 for patients 
with <G2 lung toxicity. 
Conclusions: In our study, various dosimetric and clinical parameters 
did not predict for clinical toxicity. Further analysis is required to see 
if there are any other predictive metrics for lung toxicity in this 
challenging population. In addition, in this analysis we have used a 
higher D2cm as a surrogate for potential higher rib dose and we will 
perform formal dosimetric analysis of the rib dose to assess if there is 
a correlation between dose and rib toxicity 
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Purpose/Objective: In India, 63,000 new lung cancer cases are 
diagnosed annually with two-thirds in stage III and IV at presentation. 
Even in metastatic disease, predominant symptoms include chest 
symptoms for which local treatment is often required. Radiotherapy 
(RT) is an excellent modality to relieve these symptoms, however, 
optimal dose and fractionation needs to be ascertained. To assess the 
impact of short regimen RT in patients with advanced lung cancer. 
Materials and Methods: Retrospective audit of consecutive patients of 
advanced lung cancer (NSCLC & SCLC), receiving palliative thoracic 
radiotherapy (TRT) during the period from January 2012 to mid 
November 2012 was conducted. Patient related factors age, gender, 
smoking habits, predominant symptom, comorbidity, performance 
score (ECOG), tumour related factors stage, histology were recorded. 
TRT was planned using megavoltage radiation with conservative 
treatment volume by giving smaller margin to gross disease. 
Treatment related factors (RT dose,dose fractionation), use of 
systemic therapy were recorded. Subjective response to RT 
(improvement in symptom index) was recorded. Overall survival was 
calculated. 
Results: Of 68 patients treated with palliative TRT during this period 
with median age 57 years (range 24-80 years), 57 patients were males, 
31 smokers, 48.5% in stage III at presentation and 51.5% in stage IV. 
The NSCL cancer (squamous cell-26, adenocarcinoma-21, NOS-8) and 
remaining were SCLC. 38 patients had ECOG PS ≥2. The predominant 
symptoms included pain (48.5%), cough with pain (14.7%), dyspnea 
(11.8%), SVCO (11.8%), cough (7.4%), pain with dyspnea (2.9%) and 
2.9% patients had brachial plexopathy. Of these, 50 patients were 
treated with short course once weekly schedule using 16Gy/2 
fractions or 17Gy/2fractions, considering the volume to be treated. 
Seven patients did not receive second fraction due to various reasons. 
Twelve patients required analgesics for pain relief. 40 patients had 
greater than 50% relief in the symptoms after once weekly 
radiotherapy with a median duration of symptom relief of 2 months. 
42 patients received systemic treatment. At last recorded follow-up, 
17 patients had died due to disease progression. Median overall 
survival was 3.5 months. 
Conclusions: Short course RT provides good intra-thoracic symptom 
relief in advanced lung cancer patients with compromised PS. 
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Purpose/Objective: VMAT uses continuous gantry rotation to deliver 
multiple beam segments and has the advantage of faster treatment 
delivery compared to standard conformal radiotherapy. This 
technique has the theoretical advantage of better sparing of organs, 
but there is concern that larger volumes of low dose irradiation may 
increase toxicity. This study assessed if 3D conformal planning 
constraints are valid for VMAT planning and to determine toxicity and 
survival outcomes. 
Materials and Methods: Data on patients with lung carcinoma (stage I-
IIIB) and oesophageal carcinoma (stage III) who were treated with 
VMAT were obtained retrospectively. Radiotherapy treatment was 
planned using Autobeam version 4.6. Stage III lung patients received 
induction or concurrent chemotherapy, and oesophagus patients 
received induction chemotherapy followed by chemoradiotherapy. 
Patients were assessed weekly for toxicity during treatment, and then 
at 3-6 monthly intervals up to 2years. Toxicity was graded according 
to the Common Toxicity Criteria (CTC)v4.0. Doses received by the 
heart, lung, oesophagus, spinal cord, and liver were evaluated. An 
oesophageal dose constraint was not applied. Statistical analyses were 
performed to assess the relationship between dose volume parameters 
and toxicity. Outcome data was analysed using Kaplan-Meier survival 
curves. 
Results: 68 patients (42lung, 26 oesophagus) were treated between 
7/4/2008 and 31/1/2012, and received doses ranging from 50-64 Gy. 
The average age was 67.8 years (range 43-81). The median duration of 
follow-up was 11.6 months. The mean lung dose was 11.2 Gy (range 
3.13-19.41). 8.8% (6/68) and 4.4% (3/68) patients experienced≥ Grade 
2 pneumonitis at 3 and 6 months respectively. There was no 
significant correlation between pneumonitis and lung dose volume 
parameters at all levels.Overall 8/42 (19%) lung patients experienced≥ 
grade 2 oesophageal toxicity. In patients who experienced Grade 2-4 
oesophageal toxicity, median “Oesophagus V35” was 41% vs. 23% in 
those who had Grade 0-1 toxicity.Mann Whitney U test showed a 
significant difference in the V35 between these 2groups of patients. 
(U=70, p=0.00375). No late cardiac or lung toxicity ≥ Grade 2 was 
observed. Late oesophageal toxicity occurred in 4.4% (3/68). Median 
progression free survival (PFS) was 12.0 months (95% CI8.1-15.9) in 
lung patients, 7.6 months (95% CI 0.0-15.2) in oesophageal patients, 
and 11.9 months (95% CI 8.8-15.0) overall .  
Conclusions: VMAT was well tolerated by our patient cohort, with 
acceptable pneumonitis and oesophageal toxicity rates. Outcomes are 
comparable with patients treated with 3D conformal radiotherapy 
with no additional late toxicity.  
 
